10 recruiting, 9 completed, 4 active not recruiting, 2 not yet recruiting. 12 Phase 1, 11 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 9, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 11 | Recruiting 7, Active not recruiting 2, Not yet recruiting 2 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow Nemtabrutinib: new trials by email Literature Review of Nemtabrutinib trials Research Report on Nemtabrutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-04 | 2026-10-30 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) Nemtabrutinib - Severe Renal Impairment, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-09-08 | 2026-09-23 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-07-31 | 2026-08-17 |
| A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) Nemtabrutinib, Diltiazem - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 26 | 2025-12-08 | 2026-06-29 |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 27 | 2025-01-22 | 2026-03-13 |
| A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) Nemtabrutinib - Hepatic Impairment (HI) | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2024-07-24 | 2026-09-02 |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Nemtabrutinib, Ibrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1200 | 2023-12-13 | 2026-10-13 |
| A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012) Digoxin, Nemtabrutinib - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2023-11-07 | 2024-10-03 |
| A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013) Nemtabrutinib, Itraconazole - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 15 | 2023-10-30 | 2024-11-14 |
| A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017) Nemtabrutinib - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 20 | 2023-10-02 | 2025-01-14 |
| A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007) Nemtabrutinib - Hematological Malignancy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 40 | 2023-08-28 | 2024-09-19 |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 735 | 2023-08-08 | 2026-10-15 |
| A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014) Nemtabrutinib, Efavirenz - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2023-07-25 | 2024-11-20 |
| A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016) Nemtabrutinib - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 18 | 2023-07-24 | 2025-01-14 |
| A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) Nemtabrutinib, Fludarabine, Cyclophosphamide - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2023-03-16 | 2026-03-16 |
Showing 20 of 25. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (10) · Hematologic Neoplasms (4) · Lymphoma, Mantle-Cell (4) · Leukemia, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hemorrhagic Disorders (1)
Merck Sharp & Dohme LLC (16) · City of Hope Medical Center (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Fred Hutchinson Cancer Center (1) · Jennifer Woyach (1) · Medical College of Wisconsin (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Roswell Park Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1)
United States (23) · Brazil (5) · China (5) · Turkey (Türkiye) (5) · Australia (4) · Canada (4) · Chile (4) · Germany (4) · Israel (4) · Japan (4) · Poland (4) · Spain (4) · United Kingdom (4) · Colombia (3) · Czechia (3)
Alexey V Danilov (1) · Bhagirathbhai Dholaria (1) · Geoffrey Shouse (1) · Guru S Guru Murthy, MD (1) · Jennifer A Woyach, MD (1) · Jennifer Huang, MD, PhD (1) · Laura S Samples, M.D. (1) · Matthew J Cortese (1)
PMID 34398557, PMID 37930156, PMID 41363770
P30CA033572 (2), 2023 (1)